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Abstract
Background—Genome-wide aberrations of the classic epigenetic modification 5-methylcytosine 
(5mC), considered the hallmark of gene silencing, has been implicated to play a pivotal role in 
mediating carcinogenic transformation of healthy cells. Recently, three epigenetic marks derived 
from enzymatic oxidization of 5mC namely 5-hydroxymethylcytosine (5hmC), 5-formylcytosine 
(5fC) and 5-carboxylcytosine (5caC), have been discovered in the mammalian genome. Growing 
evidence suggests that these novel bases possess unique regulatory functions and may play critical 
roles in carcinogenesis.
Methods—To provide a quantitative basis for these rare epigenetic marks, we have designed a 
biotin-avidin mediated Enzyme-based Immunoassay (EIA) and evaluated its performance in 
genomic DNA isolated from blood of patients diagnosed with metastatic forms of lung, pancreatic 
and bladder cancer, as well as healthy controls. The proposed EIA incorporates spatially optimized 
biotinylated antibody and a high degree of horseradish-peroxidase (HRP) labeled streptavidin, 
facilitating signal amplification and sensitive detection.
Results—We report that the percentages of 5mC, 5hmC and 5caC present in the genomic DNA 
of blood in healthy controls as 1.025 + 0.081, 0.023 + 0.006 and 0.001 + 0.0002 respectively. We 
observed a significant (p<0.05) decrease in the mean global percentage of 5hmC in blood of 
patients with malignant lung cancer (0.013 + 0.003 %) in comparison to healthy controls.
Conclusion—The precise biological roles of these epigenetic modifications in cancers are still 
unknown but in the past two years it has become evident that the global 5hmC content is 
drastically reduced in a variety of cancers. To the best of our knowledge, this is the first report of 
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decreased 5hmC content in the blood of metastatic lung cancer patients and the clinical utility of 
this observation needs to be further validated in larger sample datasets.
Keywords
5-methylcytosine (5mC); 5-hydroxymethylcytosine (5hmC); 5-formylcytosine (5fC); 5-
carboxylcytosine (5caC); Enzyme-based Immunoassay (EIA); Cancer; Epigenetic modifications
1. Introduction
The addition of a methyl group (-CH3) at the C-5 position of the pyrimidine ring of cytosine 
nucleotide, mediated by a family of DNA methyltransferases, serves as an epigenetic 
signaling tool employed by cells to “turn off” the expression of the implicated genes [1–3]. 
This epigenetic modification also known as 5-methylcytosine (5mC) plays an important role 
in numerous cellular processes including embryonic development, genomic imprinting, 
cellular differentiation and preservation of genomic stability [4, 5]. Recently, three other 
enzymatically (TET family of dioxygenases) mediated epigenetic derivatives of 5mC 
namely 5-hydroxymethylcytosine (5hmC;-CH2OH group at Cytosine C-5) [6, 7], 5-
formylcytosine (5fC; -CHO at Cytosine C-5) [5, 8] and 5-carboxylcytosine (5caC;-COOH at 
Cytosine C-5) [3, 5] have been discovered. These derivatives serve as intermediates in the 
DNA demethylation pathway and are believed to confer unique transcriptional potential to 
genes [3, 9–12].
Epigenetic alterations are very important in determining cellular fate and their aberrations 
are frequently observed during initiation and progression of cancers [2, 3]. Locus-specific 
DNA methylation markers such as DNA hypermethylation of Breast cancer type 1 
susceptibility (BRCA1) gene in breast and ovarian cancer [13], Death-associated protein 
kinase (DAPK) gene in bladder cancer [14], O-6-methylguanine-DNA methyltransferase 
(MGMT) gene in colorectal and lung cancers [15, 16] have been proposed as prognostic and 
diagnostic biomarkers in clinical settings. Alterations of global levels of 5mC have been 
reported in early neoplasia and solid tumors [17–19]. For instance, there are reports 
suggesting a fundamental association between global methylation levels and tumor 
aggressiveness, regardless of the origin of cancer tissue [20–24]. Recently, extensive loss of 
5hmC has been observed in multiple cancer types like lungs, prostate, breast, colon, brain 
and blood [3, 9–11, 25] suggesting a potential role of 5hmC in cancer development. Also in 
addition to 5hmC, since other critical enzymatic components (TET family of dioxygenases, 
Isocitrate dehydrogenase enzyme family and DNA repair enzyme thymine DNA 
glycosylase) of the dynamically balanced DNA demethylation have been implicated in 
cancers [26], the downstream components of the pathway - 5fC and 5caC - might also have 
different roles in cancers and need to be explored [27, 28]. Therefore, quantitative analysis 
on genome-wide distribution of these epigenetic marks (epimarks) has been critically 
considered for clinical applications. In particular, information on alterations of epimarks 
could prove useful in identifying cancer in its early stages for prognosis or monitor the 
success of administered therapies in cancer patients..
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The classical method to quantify global DNA methylation is based on sophisticated 
instruments such as liquid chromatography and more recently accompanied with mass 
spectrometric techniques (LC-MS) [5, 29]. While methods based on the principles of LC-
MS are quantitative and reproducible; these methods are complex, exorbitantly priced, 
require skilled personnel and presently unsuitable for high throughput analyses [30, 31]. 
Conventional immunoassays, employing HRP-conjugated-antibody, have widely been used 
as a quantitative method due to its analytical merits (high sensitivity, high-throughput utility, 
cost-effectiveness and ease of use) for the analyses of various biomarkers [29, 32]. Recent 
reports on the quantification of 5mC and 5hmC from different tissues and cell lines based on 
immunoassay principles [32] have been commercialized [33–35]. However, these 
immunoassays cannot be currently used for clinical diagnosis because they lack sensitivity 
(particularly in the assessment of 5hmC, 5fC and 5caC) and are expensive. Thus we propose 
a biotin-avidin mediated EIA with enhanced signal output using spatially optimized 
biotinylated antibody coupled with streptavidin with a high degree of HRP labeling for the 
detection of 5mC, 5hmC, 5fC and 5caC (refer to Figure 1a). This method was first compared 
with conventional immunoassay method and upon satisfactory performance, applied to 
detect the rare DNA epimarks in the blood of metastatic cancer patients.
2. Materials and Methods
2.1 Materials
DNA coating solution, succinimidyl-6-[biotinamido]-6-hexanamidohexanoate (NHS-LC-LC 
biotin), succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxy-(6-amidocaproate) 
(LC-SMCC), succinimidyl 6-[3(2-pyridyldithio) propionamido] hexanoate (LC-SPDP), 
dithiothreitol (DTT), horseradish peroxidase (HRP), Sephadex G-15, mouse anti-rabbit IgG 
and goat anti-mouse IgG were purchased from Pierce (Rockford, IL). Casein, Tween 20, 
tetramethylbenzidine (TMB), ethylenediaminetetraacetic acid disodium salt (EDTA) were 
obtained from Sigma (St. Louis, MO). Rabbit antibodies specific to 5hmC, 5fC and 5caC 
were supplied by Active Motif (Carlsbad, CA). Mouse anti-5mC was purchased from 
Eurogentec (Fremont, CA). Four epigenetic DNA standards to be used as positive controls: 
(i) 5mC and (ii) 5hmC from Zymo Research (Irvine, CA), (iii) 5fC from Epigentek 
(Farmingdale, NY) and (iv)5caC from Active Motif (Carlsbad, CA) were purchased. 
Streptavidin was purchased from Prozyme (Hayward, CA).
2.2 Clinical Sample Preparation
Biospecimens were collected from patients with lung, bladder or pancreatic cancers and 
healthy controls by Hoosier Oncology Group, Indianapolis, IN as part of the study entitled, 
“A Biological Sample Collection Protocol of Patients with and without Metastatic Solid 
Organ Malignancies: Hoosier Oncology Group Study BANK09-138”. Blood samples were 
centrifuged at 3,500 rpm for 30 minutes and stored at −70°C. All studies were approved by 
Institutional Review Boards (IRB) protocols at their respective institutions. Informed 
consent forms were obtained from all subjects. Genomic DNA was isolated from the 
biospecimens using QIAamp DNA Mini and Blood kit (Qiagen Inc., Valencia, CA) 
following manufacturer’s instructions. Information on clinical samples is presented in 
Supplementary Table 1. DNA was quantified by NanoDrop 1000 Spectrophotometer 
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(Thermo Fisher Scientific Inc., Waltham, MA). Absorbance of the DNA samples was 
collected at 260 and 280 nm with a conventional 10 mm path length. The DNA 
concentration in (ng/µl) was determined by absorbance at 260 nm based on Beer’s Law. The 
ratio of absorbance at 260 and 280 nm was used to assess the purity of the DNA.
2.3 Preparation of Biotinylated secondary antibody
500 µg of mouse anti-rabbit or goat anti-mouse IgG secondary antibody (2 mg/ml) was 
labeled with 50-fold molar excess of NHS-LC-LC-biotin (dissolved in DMSO) using 10 
mM phosphate buffer with 150 mM NaCl (pH 7.4) as the reaction buffer. The reaction was 
carried out at room temperature for 1 hour and the biotinylated antibody was purified by 
dialysis (dialysis buffer: 10 mM phosphate buffer contained 150 mM NaCl, pH 7.4) 
followed by size exclusion chromatography on Sephadex G-15 gel column where free biotin 
or biotin not conjugated to the secondary antibody was removed.The prepared antibodies 
were concentrated and stored in 10 mM phosphate buffer containing 150 mM NaCl (pH 7.4) 
at 4°C until further use. Bradford assay was employed to determine a concentration of 
labeled antibodies. The molar ratio of biotin to antibody in the biotinylated-antibody 
conjugates was evaluated by the HABA (4'-hydroxyazobenzene-2-carboxylic acid) Biotin 
quantification assay, as described previously [36].
2.4 Conjugation of streptavidin with HRP
1 mg of Streptavidin was first coupled to 50 molar excess LC-SPDP for 1 hour followed by 
treatment with DTT (10 mM final concentration) for reduction of dithiol groups at room 
temperature for 30 minutes and purified via Sephadex G-15 gel filtration column, which was 
pre-equilibrated in 10 mM PBS buffer containing 5 mM EDTA. By following a similar 
procedure, 3.7 mg HRP was activated by LC-SMCC and purified [37]. The thiolated 
streptavidin and maleimide-activated HRP (molar ratio 1:5) were then mixed at room 
temperature for 2 hours with gentle shaking to enable conjugation. This mixture was 
thereafter stored at 4°C until further use. The enzymatic activities of both unconjugated and 
streptavidin-conjugated HRP were tested via enzyme assay on microtiter plate. 0 and 0.1 
fmol/mL of unconjugated as well as streptavidin-conjugated HRP were reacted with 
substrate solution containing hydrogen peroxide and tetramethyl benzidine.
2.5 Analytical procedure of the biotin-avidin mediated EIA
To quantitate the four target epimarks, genomic DNA (100 ng for quantification of global 
5mC content and 200 ng for quantification of global 5hmC, 5fC or 5caC content) isolated 
from the clinical biospecimens was first coated on polystyrene surface of a microwell with 
DNA coating solution (100 µL) at room temperature for 2 hours with gentle agitation. After 
washing 3 X 5 minutes in PBS-Tween 20 and once with PBS, the residual surface was 
blocked with 0.5% (w/v) casein in PBS at 37°C for 1 hour. Subsequently, incubation with 
primary antibody (0.5 µg/mL, 100 µL) recognizing 5mC, 5hmC, 5fC or 5caC diluted in PBS 
containing 0.5% casein and 0.1% Tween 20 was performed for 1 hour at 37 °C. After 
thorough washings, biotinlyated antibodies specific to each primary antibody (0.5 µg/mL,
100 µL) was added and incubated for 1 hour at 37 °C. Finally, streptavidin conjugated to 
HRP (0.25 µg/mL, 100 µL) was added and incubated for 1 hour at 37 °C. For signal 
generation, 200 µL of the colorimetric substrate mixture [1000: 10: 1 volume ratio of the 
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following (a) 50 mM sodium acetate buffer, pH 5.1, (b) 1% (w/v) tetramethylbenzidine and 
(c) 3% (v/v) H2O2] was added to the microwell and maintained for 15 minutes at room 
temperature followed by the addition of 50 µL of 2 M sulfuric acid to stop the reaction. The 
optical intensity was finally measured at 450 nm with the Versamax™ absorbance 
microplate reader (Molecular Device; Sunnyvale, CA). To quantitatively compare with the 
EIA, conventional EIA was performed under the same conditions except for using secondary 
antibody labeled with HRP instead of using biotinylated secondary antibody and 
streptavidin-HRP conjugate. The Limits of Detection (LOD) have been calculated by a 
statistical method [38–40] based on
S.D → standard deviation of the response and
m → slope of the calibration curve (= dY/dX)
2.6 Quantitative analysis – Calibration curve
To establish calibration curve, increasing amounts of standard DNA bearing 5mC, 5hmC, 
5fC or 5caC was coated on the microwell surface and immunoassay performed as described 
above. The signals obtained were plotted, and linear regression curve and R-square were 
calculated for quantification of epimarks in unknown samples as per the following 
equations:
Equation 
(i)
Equation 
(ii)
The normalized sample O.D450 nm was obtained from subtracting the O.D450 nm of the blank 
sample (no genomic/standard DNA added, but subsequent steps performed similarly) from 
the observed sample O.D450 nm. ‘n’ denoted a factor to normalize the respective epigenetic 
derivatives in the positive standard DNA to 100% (5mC, 5hmC and 5caC content in the 
respective positive standard DNAs being 24.9%, 24.9% and 15.7%). T-test was used to 
evaluate the statistical significance of the differences of levels of the DNA epimarks in the 
biospecimens of the metastatic cancer and healthy counterparts [41, 42].
3. Results
3.1 Analytical concept
In the proposed EIA, the obtained signal intensities were directly proportional to the amount 
of the epimarks. The DNA extracted from the clinical samples and subsequently used as 
input for EIA was of high purity (A260/280: 1.7–1.9) and yield (4–6 µg/ 200 µl of blood). 
As described in the Methods Section, the first procedure in the proposed platform after 
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specific recognition of epimarks by the respective primary antibodies involved incorporation 
of biotinylated-secondary antibody. Here, several amine-reactive biotin cross-linkers with 
different lengths (ranging from 1 to 3 nm) were tested and NHS-LC-LC-biotin linker (with a 
length of 3 nm) was selected to be optimal. HABA (4'-hydroxyazobenzene-2-carboxylic 
acid) assay [36] estimated that 4.5 molecules of biotin were bound per molecule of 
secondary antibody. The final concentration of the biotinylated antibody was determined to 
1 mg/ml by Bradford assay. The increased number of biotin on the secondary antibody 
facilitates multiple enzymes (i.e., HRP) tagged streptavidin to bind with the secondary 
antibody, which in turn remains optimally bound to the epimark recognizing primary 
antibody as shown in Figure 1a and thereby achieves a higher degree of labeling. For the 
best analytical performances, each streptavidin moiety was labelled with multiple HRP by 
controlling length of linkers to be extended up to 3 nm (sum of length of LC-SPDP and LC-
SMCC), facilitating reduction of steric hindrance and favoring a high degree of labelling 
(three to four HRP per streptavidin which was verified by SDS-PAGE). The peroxidase 
activities of both unconjugated HRP and streptavidin-conjugated HRP were compared and 
did not indicate any significant difference in producing the color signal. Conventionally, 
since unconjugated HRP molecules do not participate in avidin-biotin reaction and are 
subsequently removed during the washing procedures, purification of the final conjugate is 
not deemed necessary.
3.2 Calibration Curve and Specificity Determination
To accurately quantitate the percentages of each epimark in genomic DNA, four types of 
standard curves were prepared by plotting the optical densities at 450 nm wavelength versus 
the amount of standard input DNA (picogram, pg unit) as shown in Figure 1 c-f. The results 
obtained from the proposed EIA demonstrate that the limit of detection (LOD) of each mark 
to be as follows: 3.802 pg for 5mC, 0.543 pg for 5hmC, 3.139 pg of 5fC standard DNA and 
0.209 pg for 5caC and was suitable for detection of the rare epimarks in the scarce 
metastatic biospecimens. The proposed EIA examined here can be regarded as 
heteroscedastic because of some of the steps involved in the procedure like the NanoDrop’s 
UV-vis absorption spectrometry, manual handling and pipetting errors. Nevertheless, the 
above interpretation retains the fundamental concept of the original assumption of 
homoscedasticity i.e if the analyte of LOD concentration is measured, the probability of the 
measurements falling below the limit of decision is 5% [40]. In addition, the linearized 
regression curves have a high R-square value and low standard deviation, enabling reliable 
quantification of the corresponding marks from unknown samples (Kindly see 
Supplementary Tables 2–5 for inter-assay % coefficient of variation and Supplementary 
Tables 6–9 for intra assay % coefficient of variation). Furthermore, due to coexistence of the 
four epimarks in genomic DNA, it is critical to eliminate cross-reactivity which is 
considered as one of the major analytical factors for evaluation of the assay. Multiple cross-
reactivity tests were performed to demonstrate high specificity without significant cross-
reactivity in the EIA (illustrated in Figure 1b).
3.3 Clinical Application
We decided to put our proposed EIA to test on a limited dataset (n=27) of rare metastatic 
biospecimens and determine the content of the epigenetic derivatives in cancers. The level 
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of 5mC was the most abundant amongst the four epimarks and constituted a mean value of 
1.025 + 0.081 % of the genome in healthy controls. The 5mC content of the metastatic lung, 
bladder and pancreatic cancer biospecimens was not found to be significantly altered from 
the mean 5hmC content of healthy controls (Figure 2a). The mean 5hmC content of healthy 
controls was determined to be 0.023 + 0.006 % of the genome. In comparison to 5mC, inter-
sample variability of 5hmC was found to be higher but consistent with earlier findings [43]. 
The mean 5hmC content of the lung cancer biospecimens was found to be 0.013 + 0.003 % 
of the genome (significantly lower at p <0.05), while no significant difference in the mean 
5hmC content of pancreatic and bladder cancer biospecimens was observed in comparison 
to the healthy controls (Figure 2b). The precise levels of 5fC in the biospecimens could not 
be accurately calculated as the percentage of 5fC in the 5fC DNA standard was not disclosed 
by the manufacturer for reasons of proprietary and the normalization factor ‘n’ of equation 
(i) (described in Materials and Methods section) could not be determined. However, the 
normalized O.D450 nm readouts did not show any significant difference between the cancer 
biospecimens and their healthy counterpart. The mean 5caC content was determined to be 
0.001 + 0.0002 % of the genome in healthy controls and was not found to be significantly 
altered in the cancer biospecimens (Figure 2c).
4.0 Discussion
It is increasingly evident that the status of DNA methylation and its derivatives is linked to 
mechanisms of cancer predisposition [3, 21, 42, 44]. Thus, profiling DNA methylation 
derivatives in whole blood as a predictive marker for metastatic cancer is of particular 
interest because peripheral blood is a convenient tissue to assay and its collection is non-
invasive [45]. The blood samples utilized in this study were derived from patients diagnosed 
at metastatic stage of cancer (Supplementary Table 1) where distant metastases was detected 
(M1 Stage in TNM classification scheme) and could serve as a proxy tissue for practical 
purposes [46]. The high affinity of avidin for biotin [47] forms the fundamental basis of the 
biotin-avidin mediated EIA. Multiple HRP labeled avidin can bind to biotin labeled 
antibody, forming the biotin-avidin complex and thereby producing enhanced intensity of 
the immune reaction. This biotin-avidin mediated EIA facilitates sensitive detection of the 
rare DNA methylation derivatives: 5mC constitutes ~1% of the genome, 5hmC (0.5 – 
<0.005%) [10], precise levels of 5fC and 5caC have not been well documented but in mouse 
ES cells it has been found to be 100-fold less frequent than 5hmC [5]. The LOD of 5mC and 
5hmC reported by several commercially available immunoassay kits based solely on HRP-
labeled secondary antibody is 20 and 10 pg respectively for a similar input range [10, 33, 34, 
48], thus the sensitivity of the biotin-avidin mediated EIA can be considered superior in 
comparison (refer to Section 3.2 for the respective LODs).
To the best of our knowledge, we report for the first time a decrease in the 5hmC content (p 
< 0.05) in the DNA extracted from blood of patients diagnosed with metastatic lung cancer 
in comparison to healthy controls. Recently, it has been conclusively demonstrated by LC-
MS/MS technology that the 5hmC content is decreased significantly between 2–5 fold in 
human squamous cell carcinomas of the lung with respect to matched tissues of healthy 
counterparts [42]. Using semi-quantitative immunohistochemistry (IHC) and dot-blot 
methodologies, a profound reduction of the 5hmC content in human lung cancer tissues and 
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genetically engineered mouse model of lung cancer has also been reported [25]. Other than 
lung cancer, reduction of 5hmC content has also been demonstrated in prostate, breast, 
colon, brain and blood malignancies [3, 9–11, 25]. Unlike locus-specific changes, alterations 
of epimarks at the global level is rapidly gaining prominence as they generate additional 
cellular epigenetic heterogeneity, which can be used to define previously unrecognized 
subsets of cancer patients with distinct clinical outcomes. Further study of the loss of 5hmC 
in metastatic cancers may offer the promise of novel therapeutic modalities especially in 
lung cancers that are responsible for the maximum number of cancer deaths in US, with 
2013 estimates of ~159,480 [49]. A better understanding of the role of epimarks in cancer is 
bound to impact clinical outcomes [20] because of their prognostic and diagnostic utility.
Thus in conclusion, due to lack of sensitivity of conventional bioanalytical techniques for 
the detection of the rare epigenetic modifications of the DNA (5mC, 5hmC, 5fC and 5caC), 
that could be integrated into high-throughput platforms; we propose a biotin-avidin mediated 
EIA strategy with high analytical performances. The quantitative determination of epimarks 
in blood, a proxy tissue of metastatic cancers, would be a practical alternative to 
conventional methods such as tissue biopsy, enabling diagnosis of cancers with a simple 
procedure that is sensitive and more economical compared to other available technologies 
[30, 31] (Refer to Table 1). As epigenetic modifications are potentially reversible, there is a 
possibility that therapies directed at modifying the epigenome might be a reality in the future 
[3, 50, 51] and it is probable that the investigation of global levels of methylated cytosine 
derivatives could be considered in the diagnostics of cancer patients especially for 
determining clinical prognosis. We expect this method to be applicable for diagnosis of 
cancer biospecimens and with minor modifications applicable for other routine assessments.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Development of Biotin-Avidin mediated Enzyme-based Immunoassay (EIA).
• Quantitate epigenetic DNA methylated Cytosine derivatives (5mC, 5hmC and 
5caC) in blood samples.
• Ultra-sensitive assay with enhanced Limit Of Detection for the epigenetic 
marks.
• First report of reduction in global 5hmC content in the blood of metastatic lung 
cancer
• First quantitative report of levels of 5caC in blood.
Chowdhury et al. Page 12
Anal Chim Acta. Author manuscript; available in PMC 2015 December 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1. Analytical concept of biotin-avidin mediated EIA
(a) Schematic representation of the proposed EIA platform developed to quantitate the 
content of the four epimarks (5mC, 5hmC, 5fC, and 5caC) contrasted with the conventional 
EIA (employing HRP labeled secondary antibody). Enhanced signal detection was achieved 
by (i) controlling cross-linking between the Secondary antibody and Biotin and (ii) Multiple 
enzyme (i.e. HRP) attachment via Streptavidin conjugation. (b) Multiple Cross-Reactivity 
Test to determine the specificity of the proposed EIA. X axis denotes the respective primary 
antibody used in the EIA (anti- 5mC, 5hmC, 5fC or 5caC), Z axis denotes the positive 
controls (DNA standard that is either methylated, hydroxymethylated, formylated or 
carboxylated; Refer to the key) immobilized to the microwells and Y axis denotes the 
corresponding colorimetric signal (absorbance at 450 nm) generated. Other than the specific 
primary antibody and the type of DNA standard immobilized indicated, the rest of the EIA 
was performed using identical conditions. (c-f) Calibration curves for quantitation of the 
precise content of 5mC, 5hmC, 5fC and 5caC in the genome, respectively. Values denoted 
in red were obtained on performing the proposed EIA, while values denoted in blue were 
obtained on performing conventional EIA. Error bars indicate standard deviations between 
technical replicates.
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Figure 2. Quantification of epimarks in clinical biospecimens
Mean global percentage of (a) 5mC, (b) 5hmC and (c) 5caC in the blood of the indicated 
groups of clinical samples (n=27). Error bars denote standard deviations between the clinical 
samples of each group. Star denotes significant difference in cancer biospecimens compared 
to healthy controls (p < 0.05, t-test).
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Table 1
Comparison of the proposed EIA with LC-MS/MS and commercial EIA based kits, provides distinct 
advantages in terms of the optimal DNA input, Limit of Detection and cost.
Assay Optimal DNA input LOD Equipment
needed
Cost
LC-MS/MS 1000–5000 ng [52] 1.251 pg for 5mC [52],
1.411 pg for 5hmC [52],
1.55 pg for 5caC [52]
HPLC,
Mass
Spectrometer
$15 sample*
Commercial
EIA
based Kits
100 ng for 5mC [34],
>200 ng for 5hmC
[33]
20 pg for 5mC [34],
10 pg for 5hmC [33]
Colorimeter $4 – 6.8/ sample [33–35]
Biotin-avidin
mediated
EIA
100 ng for 5mC,
200 ng for 5hmC,
200 ng for 5caC
3.802 pg for 5mC
0.543 pg for 5hmC
0.209 pg for 5caC
Colorimeter $0.1/ sample
*
The cost of LC-MS/MS analysis was determined based on a quote provided by the Purdue Metabolomics Core Facility (Dr. Bruce Cooper).
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